BUCHANG PHARMA(SH:603858) 21世纪经济报道·2025-12-10 08:29Core Viewpoint - The recognition of "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" awarded to the company reflects its dual leadership in industry innovation and social responsibility, serving as a model for sustainable development in the pharmaceutical sector [1][4][13]. Group 1: Innovation and R&D - The company has been awarded "Annual Drug R&D Innovation Enterprise" due to its over 30 years of dedication to the pharmaceutical industry, with innovation as its core development engine [6]. - In 2018, the company announced a strategic transformation from a marketing-driven model to a product and technology-driven approach, expanding from traditional Chinese medicine to biopharmaceuticals, chemical drugs, medical devices, and internet medicine [6]. - The R&D investment reached 717 million yuan in 2024, an increase of 8.58% year-on-year, emphasizing the importance of continuous investment in innovation [6]. - As of mid-2025, the company holds 457 valid patents and has over 200 products under development, establishing a solid foundation for industry innovation [7]. - The company’s flagship products, including "Nerve and Heart Capsule," "Stable Heart Granule," and "Dan Hong Injection," generated a total sales revenue of 5.83 billion yuan in 2024, with a market share ranking in the top five for cardiovascular traditional Chinese medicine [7][8]. Group 2: Social Responsibility and Public Welfare - The company has been recognized as "Annual Excellent Public Welfare Enterprise" for its commitment to social responsibility, integrating public welfare into its core business [10][11]. - The "Together to Build a Chinese Heart" public welfare project has been ongoing for 18 years, benefiting over 1 million people in Tibetan regions through medical support and health initiatives [11][12]. - The company’s public welfare efforts are not merely financial donations but involve deep collaboration with its business strategy, enhancing both social impact and corporate value [12]. - Since its establishment, the company has contributed nearly 33 billion yuan in taxes, supporting local economic development [12]. Group 3: Future Outlook - The dual recognition of "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" exemplifies the company's successful "innovation + public welfare" dual-driven development model [13]. - The company aims to deepen its global layout and continue breakthroughs in biopharmaceuticals and vaccines, while expanding its public welfare projects, contributing to the "Healthy China" strategy and high-quality development of the pharmaceutical industry [13].